Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT01654133
Other study ID # 12-0644
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date July 2012
Est. completion date August 2030

Study information

Verified date February 2024
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate visceral function, after endovascular repair of thoracoabdominal aneurysms or ascending/aortic arch aneurysms.


Description:

This study will evaluate the effect of endovascular repair of thoracoabdominal aortic aneurysms (Types I-IV) on visceral function or aortic arch aneurysms using custom manufactured and off the shelf stent grafts. Specifically, the device orientation and configuration will be evaluated with respect to renal function. Since detailed CT scan imaging will be performed prior to and after endovascular repair, critical data concerning each branched vessel length, tangential orientation from the aorta, angle of incidence, and diameter can be determined. This information can then be coupled with hemodynamic data obtained from duplex ultrasonography as well as changes in renal volume, estimated glomerular filtration rate (eGFR), and flow characteristics over time. By analyzing the data in this fashion, it may be possible to determine changes in hemodynamics and/or physiologic conditions with respect to branched stent-graft design characteristics. These data may be utilized to enhance current device design and improve patient outcomes. The FDA has approved the use of commercially available devices to be used in conjunction with the investigational device if the Investigator deems this necessary.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 645
Est. completion date August 2030
Est. primary completion date August 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Cohort 1 (TAAA) Inclusion Criteria: Patients may be included in the study if the patient has at least one of the following and has aortic anatomy appropriate for treatment with the Zenith® p-Branch™, Zenith® t-Branch, or Physician Specified TAAA Endovascular Graft (Custom Manufactured Devices). 1. Aortic Aneurysm Diameter a. TAAA (Type I - IV) (including pararenal subtypes) with orthogonal aortic diameter greater than or equal to 5 cm or b. greater than two times the normal aortic diameter 2. Rapid aortic enlargement (> than or equal to 5mm in 1 year) 3. Presence of a saccular aneurysm at risk for rupture based on investigators evaluation 4. Iliac artery aneurysm ?2.2 cm may be treated with the Zenith® Branch Endovascular Graft-Iliac Bifurcation when the iliac artery aneurysm is associated with the qualifying thoracoabdominal aneurysm treated in this study Exclusion Criteria: General Exclusion Criteria Patients must be excluded from the study if any of the following conditions are true: 1. Less than 18 years of age 2. Unwilling to comply with the follow-up schedule 3. Inability or refusal to give informed consent Medical Exclusion Criteria Patients must be excluded from the study if any of the following conditions are true: 1) Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, urethane or gold 2) History of anaphylactic reaction to contrast material that cannot be adequately premedicated 3) Leaking, ruptured aneurysm associated with hypotension 4) Uncorrectable coagulopathy Anatomical Exclusion Criteria Patients must be excluded from the study if any of the following conditions are true: 1. Inadequate femoral/iliac access compatible with the required delivery systems; 2. Does not have a non-aneurysmal aortic segment proximal to the aneurysm with: a. A length of at least 4 mm, i.e. at least 4 mm circumferential wall contact around the limits of scallop b. A diameter measured outer wall to outer wall of no greater than 31mm and no less than 21 mm; c. An angle less than 60 degrees relative to the centerline of the aneurysm; d. An angle less than 45 degrees relative to the supraceliac aorta. 3. Does not have visceral vessel anatomy compatible with Zenith® p-Branch™, specifically: a. Renal vessel origins as measured relative to the superior mesenteric artery (SMA) compatible with the renal fenestration, i.e. Both renal vessel origins within 7.5mm of the corresponding renal fenestrations; b. Celiac vessel origin as measured relative to the superior mesenteric artery (SMA) compatible with the celiac scallop. 4. A proximal seal site with unsuitable thrombus/atheroma 5. Does not have iliac artery fixation sites and anatomy consistent with: 1. Common iliac artery fixation site diameter, measured outer wall to outer wall on a sectional image (CT) <8.0 mm (prior to deployment) 2. Iliac artery diameter, measured outer wall to outer wall on a sectional image (CT) >21 mm at distal fixation site 3. Iliac artery distal fixation site <10 mm in length 4. Inability to preserve at least one hypogastric artery - Cohort 2 (ascending/aortic arch) Inclusion Criteria: General Inclusion Criteria: 1. Treatment not possible with a currently available non-modified approved device 2. Patient accepts to and is able to comply with lifetime follow-up 3. Patient accepts to and is able to provide informed consent prior to enrollment 4. No stroke with significant residual deficit or myocardial infarction within the last 12 months 5. No significant carotid bifurcation disease (> 70% stenosis by NASCET criteria) 6. Absence of systemic or local infection that may increase the risk of endovascular graft infection 7. Patient determined to be a high-risk profile for open surgical repair considering any of the following items: 1. Anatomy: previous sternotomy or left-sided thoracotomy (if the proposed open repair would require dissection of the thoracic aorta), previous aortic surgery, large aneurysm abutting the sternum with risk of disruption during sternotomy, prior cervical or chest irradiation. 2. Physiology: ASA Category = III, age >70 years, previous myocardial infarction, coronary artery disease, or coronary artery stent, coronary stress test with a reversible perfusion defect, COPD, congestive heart failure Vascular Inclusion Criteria: 1. Aortic Aneurysm Diameter: Ascending and/or Arch aneurysm with or without aortic or aortoiliac aneurysm with orthogonal aortic diameter greater than two times the normal aortic diameter 2. Rapid aortic enlargement (= 5 mm in 1 year) 3. Presence of a saccular aneurysm at risk for rupture based on the investigators evaluation 4. Clinical indication for aneurysm repair based on symptoms 5. Concomitant thoracoabdominal and aortic arch aneurysm meeting one of the above-mentioned criteria. Anatomic Inclusion Criteria: 1) There is enough space for the device to be deployed distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion 2) Ascending aortic length >50 mm (greater curve distance from sinotubular junction to proximal aspect of the innominate artery) 3) Sealing zone in the ascending aorta >40 mm in length and <38 mm in diameter for native aorta (<42 mm if surgical graft replacement in place) 4) Sealing zone in the great vessels of >20 mm in length - Diameter of innominate artery used for sealing < 20 mm - Diameter of CCA or subclavian artery used for sealing < 16mm 5. Distal aortic fixation zone: Native aorta or surgical graft (endovascular device or Dacron graft) , diameter: 20-42mm, distal neck length =20mm 6) Access for device delivery to accommodate 22F or 24F sheath depending on device design. 7) Sealing zone in the great vessels of = 20 mm in length - Diameter of innominate artery used for sealing between 8 and 20 mm - Diameter of CCA or subclavian artery used for sealing between 6 and 16 mm. Extra inclusion criteria - special situations: - Aortic dissection: 1. A true lumen size large enough for device deployment and to gain access into the target branches 2. A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, so that the graft would seal off the dissection lumen 3. A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection or surgically created 4. Access into the true lumen from the groin and to at least one supra-aortic trunk vessel - If more distal disease is observed in the aorta 1. The repair might be coupled with a thoracoabdominal branched device 2. Iliac anatomy large enough to allow the delivery of the arch branch device which is loaded within a 20F-24F sheath. Iliac conduits may be set in place if necessary. Exclusion Criteria: General exclusion criteria: 1. Life expectancy less than 2 years 2. Less than 18 years of age 3. Women must not be pregnant or breastfeeding 4. Active malignancy with life expectancy less than 2 years 5. Presence of mycotic aneurysm, systemic or local infection in access sites that may increase the risk of endovascular graft infection 6. Untreatable coagulopathy 7. Coronaropathy / Unstable angina 8. Anaphylactic reaction to contrast that cannot be adequately pre-medicated 9. Cultural objection to receipt of blood or blood products 10. Allergy or sensitivity to the endografts material (stainless steel, polyester, polypropylene, solder (tin, silver), gold, or nitinol) 11. Leaking or ruptured aneurysm associated with hypotension 12. Participation in another investigational clinical or device trial, except for participation in another investigational endovascular stent-graft protocol, percutaneous aortic valve protocol, or concomitant clinical trials designed to evaluate medical therapy strategies to reduce perioperative risk during fenestrated-branched endovascular repair 13. Prior open surgical or interventional procedure within 30 days of the anticipated date of the fenestrated-branched procedure, with the exception of planned procedures to provide access for repair (e.g. staged iliac conduit, cervical debranching) or to facilitate the procedure. Anatomic Exclusion Criteria for the Cook Ascending/Arch graft 1. Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access. 2. Iliac artery diameter, measured inner wall to inner wall on a sectional image (CT) <7.0 mm at any point along access length (prior to deployment). Inability to perform a temporary or permanent open surgical or endovascular iliac conduit for patients with inadequate femoral/iliac access. 3. Proximal seal length < 40 mm 4. Proximal seal site with a circumferential thrombus/atheroma/calcium -

Study Design


Intervention

Device:
Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft
Repair of thoracoabdominal aortic aneurysms
Endovascular repair of ascending/arch aortic aneurysm using branched stent graft
Repair of ascending/arch aortic aneurysms

Locations

Country Name City State
United States UNC Heart and Vascular Chapel Hill North Carolina

Sponsors (3)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Cook Group Incorporated, UNC Hospitals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in renal function over time (up to two years) after endovascular aortic aneurysm repair various custom stent grafts Visceral function after endovascular repair of pararenal aneurysms using various custom stent grafts. Specifically, the device orientation and configuration will be evaluated with respect to renal function over time. Critical data concerning each branched vessel from radiological studies coupled with hemodynamic data obtained from renal artery duplex, changes in renal volume, eGFR, and flow characteristics at 1, 6, 12, 18 and 24 months post procedure may make it possible to determine changes in renal function. Pre-procedure and 1, 6, 12, 18, and 24 months post procedure
Secondary Time to morbidity Morbidity at 30 days, 1 & 2 years post procedure 30 days and 1 & 2 years post procedure
Secondary Time to mortality Mortality at 30 days, 1 & 2 years post procedure. 30 days and 1 & 2 years post procedure
Secondary Time to loss of stent graft integrity Evidence on contrast CT angiography of loss of stent graft integrity at 30 days, and one and two years post procedure. 30 days and 1 & 2 years post procedure
Secondary Time to migration Evidence of stent graft migration on abdominal x-rays at 30 days and 1 & 2 years. 30 days and 1 & 2 years post procedure
Secondary Endoleak Evidence of Endoleak on contrast CT angiography of abdomen 30 days and 1 & 2 years post procedure. 30 days and 1 & 2 years post procedure
Secondary Branch vessel Events Evidence of branch vessel events on contrast CT angiography and renal duplex 30 days, and 1 & 2 years post procedure. 30 days and 1 & 2 years post procedure
See also
  Status Clinical Trial Phase
Completed NCT03657979 - TAP-Block in Abdominal Aortic Surgery Phase 4
Enrolling by invitation NCT01465425 - Extracolonic Findings on Computed Tomography (CT) Colonography
Completed NCT02845167 - Effect of Preoperative Exercise on Postoperative Outcome in AAA Patients: Pilot Study N/A
Not yet recruiting NCT00358085 - NExT ERA: National Expertise Based Trial of Elective Repair of Abdominal Aortic Aneurysms: A Pilot Study Phase 3
Terminated NCT00118573 - Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair Phase 4
Completed NCT04792411 - Adherence and Acceptability of a Remote, Home-based, Pre-surgery Programme for Patients Undergoing Abdominal Aortic Aneurysm Surgery N/A
Completed NCT04930172 - TOtal tRansfemoral branCHed endovasCular tHoracoabdominal Aortic Repair Registry
Withdrawn NCT02995642 - Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation Phase 2
Completed NCT01980901 - Post-Approval Study of the Ovation™/Ovation Prime™ Abdominal Stent Graft System
Active, not recruiting NCT01698671 - InterGard Synergy Post-Marketing Surveillance Study N/A
Enrolling by invitation NCT00831870 - EndoSure Sensor for Long-term Follow-up After Endovascular AAA Repair N/A
Recruiting NCT05972018 - Liposomal Bupivacaine/Bupivacaine in RS Blocks vs. Ropivacaine in RS Blocks And Catheters Phase 4
Not yet recruiting NCT02997618 - The AAA Get Fit Trial: A Pilot Randomised Controlled Trial of Community Based Exercise in Patients With Abdominal Aortic Aneurysms N/A
Active, not recruiting NCT02907762 - Aorfix Intelliflex First in Human Study
Completed NCT00349947 - Exercise Therapy to Treat Adults With Abdominal Aortic Aneurysms Phase 1
Completed NCT04080557 - Abdominal Aortic Aneurysm Patients Remain at Risk for Delirium on the Surgical Ward After Intensive Care Unit Dismissal
Recruiting NCT05484115 - Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck N/A
Recruiting NCT04503395 - ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES N/A
Completed NCT02867501 - Venous Distension in Patients With Aneurysmatic Arterial Disease N/A
Recruiting NCT02345590 - Eplerenone in the Management of Abdominal Aortic Aneurysms Phase 4